Related Experiment Video

Updated: Jun 3, 2026

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

[Effects of JAK2/STAT3 signaling pathway on angiogenesis in non-small cell lung cancer]

Mei Zhao1, Feng Liu, Jiong-Yi Wang

  • 1Department of Oncology, the Third People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201900, China.

Zhonghua Yi Xue Za Zhi
|March 23, 2011
PubMed
Abstract

Insights

The janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway drives angiogenesis in non-small cell lung cancer (NSCLC). Blocking this pathway may inhibit tumor growth by reducing vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Context:

  • Angiogenesis is crucial for non-small cell lung cancer (NSCLC) progression.
  • The janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway is implicated in various cancers.
  • Understanding the role of JAK2/STAT3 in NSCLC angiogenesis is essential for developing targeted therapies.

Purpose:

  • To investigate the link between the JAK2/STAT3 pathway and angiogenesis in NSCLC.
  • To determine the effect of blocking JAK2/STAT3 on the mRNA expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).

Summary:

  • Immunohistochemistry revealed a correlation between activated JAK2/STAT3 signaling and microvessel density (MVD) in NSCLC tissues.
  • Pharmacological inhibition (AG490) and genetic silencing (STAT3 siRNA) of the JAK2/STAT3 pathway reduced VEGF and bFGF mRNA levels in lung cancer cells.
  • These findings indicate that the JAK2/STAT3 pathway is a key regulator of angiogenesis in NSCLC.

Impact:

  • The JAK2/STAT3 pathway represents a potential therapeutic target for inhibiting angiogenesis in NSCLC.
  • Blocking this pathway could offer a novel strategy for NSCLC treatment by targeting tumor neovascularization.
  • This research contributes to the understanding of molecular mechanisms driving NSCLC and provides a basis for future clinical investigations.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...